1020 - 1135 GMT+9
Monday 30 August
Morning Symposium 7
Beyond disease activity: the burden of irreversible organ damage in lupus
A non-promotional symposium brought to you by Glaxosmithkline
This symposium will explore the burden of irreversible organ damage in systemic lupus erythematosus (SLE) and the factors that predict organ damage accrual. We will discuss why the prevention of irreversible organ damage is a clinical priority and outline management strategies to prevent organ damage in SLE.
Chair: Prof Xiaofeng Zeng, Peking Union Medical College Hospital, South East Asia
Irreversible organ damage in SLE
A/Prof Hirofumi Amano
Juntendo University, Department of Internal Medicine and Rheumatology Juntendo Nerima Hospital, Japan
Understanding the predictors of organ damage accrual: patient-, disease- and treatment-related factors
Prof Mengtao Li
Peking Union Medical College Hospital, South East Asia
Optimising long-term outcomes: best practices for preventing organ damage
Prof Shuang Ye
Shanghai Renji Hospital affiliated to Shanghai Jiaotong University, South East Asia
1735 - 1835 GMT+9
Monday 30 August
Evening Symposium 8
What’s next for patients with lupus nephritis?
A GSK-sponsored and -organised symposium. GSK products will be discussed.
This symposium will explore the progress made and the current challenges associated with managing patients with active lupus nephritis. Shifting treatment paradigm in SLE and LN, reviewing treatment targets and the possibility of a treat-to-target approach in patients with active lupus nephritis will be discussed. This will help to recognise how treatment practices influence long-term outcomes. Best-practice to manage patients with active lupus nephritis will be presented by reviewing clinical data and sharing real-world experience of managing these patients.
Chair: Prof Yoshiya Tanaka, University of Occupational and Environmental Health, Japan
Patients with lupus nephritis: What have we learned and where are we now?
Prof Yoshiya Tanaka
University of Occupational and Environmental Health, Japan
Treatment goals, targets and guidelines in lupus nephritis
Prof Kunihiro Yamaoka
Kitasato University School of Medicine, Japan
What’s next in lupus nephritis?
Prof Hiroaki Niiro
Kyushu University, Japan
The Prescribing Information for any GSK products discussed will be available at the meeting.
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on +44 800 221 441.
Date of preparation: July 2021